Korro Bio, Inc. — Director's Dealing 2023

Jul 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Frequency Therapeutics, Inc. (FREQ)
CIK: 0001703647
Period of Report: 2023-07-07

Reporting Person: Lucchino David L. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-07	Common Stock	S	2634	$.35	Disposed	436196	Direct
2023-07-07	Common Stock	M	9091	—	Acquired	445287	Direct
2023-07-10	Common Stock	S	2591	$.38	Disposed	442696	Direct
2023-07-10	Common Stock	M	9091	—	Acquired	451787	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-07	Restricted Stock Unit	$	M	9091	Disposed		Common Stock (9091)	Direct
2023-07-10	Restricted Stock Unit	$	M	9091	Disposed		Common Stock (9091)	Direct

Footnotes

F1: Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.

F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.34 to $0.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F3: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $0.37 to $0.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F5: The restricted stock units will fully vest on July 4, 2023.